JP2023518635A - 脳障害を処置する方法 - Google Patents

脳障害を処置する方法 Download PDF

Info

Publication number
JP2023518635A
JP2023518635A JP2022538393A JP2022538393A JP2023518635A JP 2023518635 A JP2023518635 A JP 2023518635A JP 2022538393 A JP2022538393 A JP 2022538393A JP 2022538393 A JP2022538393 A JP 2022538393A JP 2023518635 A JP2023518635 A JP 2023518635A
Authority
JP
Japan
Prior art keywords
nac
brain
subject
dose
gsh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538393A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518635A5 (https=
Inventor
ダグラス エー． グリーン，
ラジブ アール． ラタン，
トーマス アイ． ブラッドショー，
Original Assignee
ニューロネイザル， インコーポレイテッド
バーク ニューロロジカル インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューロネイザル， インコーポレイテッド, バーク ニューロロジカル インスティテュート filed Critical ニューロネイザル， インコーポレイテッド
Publication of JP2023518635A publication Critical patent/JP2023518635A/ja
Publication of JP2023518635A5 publication Critical patent/JP2023518635A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022538393A 2019-12-18 2020-12-18 脳障害を処置する方法 Pending JP2023518635A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962949640P 2019-12-18 2019-12-18
US62/949,640 2019-12-18
US202062970254P 2020-02-05 2020-02-05
US62/970,254 2020-02-05
PCT/US2020/066179 WO2021127541A1 (en) 2019-12-18 2020-12-18 Methods of treating brain disorders

Publications (2)

Publication Number Publication Date
JP2023518635A true JP2023518635A (ja) 2023-05-08
JP2023518635A5 JP2023518635A5 (https=) 2024-07-03

Family

ID=76437600

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538393A Pending JP2023518635A (ja) 2019-12-18 2020-12-18 脳障害を処置する方法

Country Status (7)

Country Link
US (3) US12090130B2 (https=)
EP (1) EP4076425A1 (https=)
JP (1) JP2023518635A (https=)
CN (1) CN115484945A (https=)
AU (1) AU2020407239B2 (https=)
CA (1) CA3165422A1 (https=)
WO (1) WO2021127541A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020380291A1 (en) * 2019-11-04 2022-05-26 Neuronasal, Inc. Use of magnetic resonance spectroscopy to calibrate and select doses, formulations, and devices for intra-nasal administration of N-acetylcysteine
CA3165422A1 (en) * 2019-12-18 2021-06-24 Neuronasal, Inc. Methods of treating brain disorders
WO2022067232A1 (en) * 2020-09-28 2022-03-31 Commercial Automation, Llc Food product storage and vending kiosk
CA3193558A1 (en) * 2020-10-01 2022-04-07 Lyra Therapeutics, Inc. Osmotic drug delivery implants
US12594254B2 (en) * 2022-02-07 2026-04-07 Neuronasal, Inc. Intranasal administration of n-acetylcysteine and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204393A1 (en) * 2017-05-02 2018-11-08 Neuronasal, Llc Use of n-acetylcysteine to treat central nervous system disorders
WO2019084543A1 (en) * 2017-10-27 2019-05-02 Beyond Barriers Therapeutics, Inc. ENHANCED ANTIOXIDANT ADMINISTRATION FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS INVOLVING OXIDATIVE STRESS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090234011A1 (en) * 2005-04-21 2009-09-17 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
EP2749552B1 (en) 2007-04-17 2015-11-18 Codman & Shurtleff, Inc. Curcumin-resveratrol hybrids
CA2871774C (en) 2012-04-26 2021-05-18 Sentient Lifesciences, Inc. Use of n-acetylcysteine amide in the treatment of disease and injury
ES2844199T3 (es) 2013-04-16 2021-07-21 Childrens Hospital Philadelphia Composiciones y métodos para el tratamiento de lesiones cerebrales
BR112017025499A2 (pt) 2015-05-28 2018-08-07 Baylor College Medicine benefícios da suplementação com n-acetil cisteína e glicina para melhorar os níveis de glutationa
CA3165422A1 (en) * 2019-12-18 2021-06-24 Neuronasal, Inc. Methods of treating brain disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204393A1 (en) * 2017-05-02 2018-11-08 Neuronasal, Llc Use of n-acetylcysteine to treat central nervous system disorders
WO2019084543A1 (en) * 2017-10-27 2019-05-02 Beyond Barriers Therapeutics, Inc. ENHANCED ANTIOXIDANT ADMINISTRATION FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS INVOLVING OXIDATIVE STRESS

Also Published As

Publication number Publication date
US12414929B2 (en) 2025-09-16
CA3165422A1 (en) 2021-06-24
US20240390313A1 (en) 2024-11-28
EP4076425A1 (en) 2022-10-26
US12090130B2 (en) 2024-09-17
WO2021127541A1 (en) 2021-06-24
CN115484945A (zh) 2022-12-16
US20210186911A1 (en) 2021-06-24
AU2020407239B2 (en) 2025-11-27
AU2020407239A1 (en) 2022-07-28
US20260007626A1 (en) 2026-01-08

Similar Documents

Publication Publication Date Title
US12414929B2 (en) Methods of treating brain disorders
US7855176B1 (en) Reduced volume formulation of glatiramer acetate and methods of administration
US20230321020A1 (en) Magnetic resonance spectroscopy to calibrate and select doses, formulations, and devices for intra-nasal administration of n-acetylcysteine
US20220372066A1 (en) Human squalamine derivatives (ent-06), related compositions comprising the same, and method of using the same
ES2740355T3 (es) Métodos para mejorar los síntomas de asma mediante el uso de benralizumab.
CN110494140A (zh) 用于自闭症谱系障碍药物治疗的方法
Tanne et al. Severe tramadol overdoses in children: a case series admitted to paediatric intensive care unit
US20240024267A1 (en) Methods of administering glutathione precursors
CN114828960A (zh) 治疗儿童个体的cln2病的方法
US12594254B2 (en) Intranasal administration of n-acetylcysteine and uses thereof
TW202342049A (zh) 治療患有腦損傷的患者的方法以及增加患有腦損傷的患者的擴展版格拉斯哥結局量表的值的方法
CN121175045A (zh) 用于治疗夏科-马里-图思病的组合物和方法
Ivaturi Intranasal and rectal diazepam for rescue therapy: Assessment of pharmacokinetics and tolerability
Mistry et al. Neuromuscular Respiratory Failure
HK40077860A (en) Methods for treating cln2 disease in pediatric subjects
MISTRY et al. 7 Neuromuscular Respiratory Failure
HK1152249B (en) Reduced volume formulation of glatiramer acetate and methods of administration

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250528

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251202